DrugPatentWatch Database Preview

Details for Patent: 7,223,440

Which drugs does patent 7,223,440 protect, and when does it expire?

Patent 7,223,440 protects BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in two NDAs.

This patent has nineteen patent family members in fourteen countries.

Summary for Patent: 7,223,440

Title:	Residual solvent extraction method and microparticles produced thereby
Abstract:	Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.
Inventor(s):	Rickey; Michael E. (Loveland, OH), Ramstack; J. Michael (Lunenburg, MA), Kumar; Rajesh (Marlborough, MA)
Assignee:	Alkermes, Inc. (Cambridge, MA)
Application Number:	11/312,371
Patent Claim Types: see list of patent claims	Formulation; Process; Use;

Drugs Protected by US Patent 7,223,440

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Astrazeneca Ab	BYDUREON BCISE	exenatide	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,223,440

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
6,824,822	Residual solvent extraction method and microparticles produced thereby	➤ Sign Up
7,875,310	Residual solvent extraction method and microparticles produced thereby	➤ Sign Up
7,524,530	Residual solvent extraction method and microparticles produced thereby	➤ Sign Up
8,187,672	Residual solvent extraction method and microparticles produced thereby	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,223,440

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	501711	➤ Sign Up
Canada	2454027	➤ Sign Up
Cyprus	1112348	➤ Sign Up
Germany	60239469	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,223,440

For more information try a trial or see the plans and pricing